Affordable Access

Access to the full text

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review

Authors
  • Fusi-Rubiano, William
  • Blow, Rebecca R.
  • Lane, Mark
  • Morjaria, Rupal
  • Denniston, Alastair K.
Type
Published Article
Journal
Ophthalmology and Therapy
Publisher
Springer Healthcare
Publication Date
Sep 18, 2018
Volume
7
Issue
2
Pages
293–305
Identifiers
DOI: 10.1007/s40123-018-0145-7
Source
Springer Nature
Keywords
License
Yellow

Abstract

Diabetic macular edema (DMO) is a leading cause of blindness in the working age population. Although anti-vascular endothelial growth factor (VEGF) therapy provided a major advance in treatment of DMO for many patients, there is a significant proportion of patients who maintain persistent DMO and have minimal response to anti-VEGF treatment. Iluvien (fluocinolone acetonide 0.19 mg [FAc]) is an important additional treatment option for DMO. In this review we describe the clinical context and the evidence for the use of the FAc implant in treating DMO, from pilot to randomized controlled studies, to later phase real world data. These studies indicate that the FAc implant is effective, well tolerated and a cost-effective option in the treatment of insufficiently responsive DMO.

Report this publication

Statistics

Seen <100 times